QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
BioAtla
(NASDAQ:BCAB)
2.31
0.04[1.76%]
At close: May 20
2.31
00
After Hours: 4:00PM EDT
Day High/Low2.16 - 2.36
52 Week High/Low2.01 - 51.83
Open / Close2.31 / 2.31
Float / Outstanding26.5M / 37.4M
Vol / Avg.321.6K / 752.6K
Mkt Cap86.4M
P/E-
50d Avg. Price4.02
Div / Yield-
Payout Ratio-
EPS-0.65
Total Float26.5M

BioAtla (NASDAQ:BCAB), Quotes and News Summary

BioAtla (NASDAQ: BCAB)

Day High/Low2.16 - 2.36
52 Week High/Low2.01 - 51.83
Open / Close2.31 / 2.31
Float / Outstanding26.5M / 37.4M
Vol / Avg.321.6K / 752.6K
Mkt Cap86.4M
P/E-
50d Avg. Price4.02
Div / Yield-
Payout Ratio-
EPS-0.65
Total Float26.5M
Benzinga - May 11, 2022, 9:27AM
Benzinga - May 5, 2022, 10:24AM
Benzinga - May 5, 2022, 4:49AM
Benzinga - May 4, 2022, 4:18PM
Benzinga - Mar 21, 2022, 6:21AM
Benzinga - Mar 1, 2022, 6:12AM
Benzinga - Feb 4, 2022, 4:14PM
Benzinga - Jan 10, 2022, 4:06PM
load more
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-12
REV
Q1 2022Est.ActualSurprise
EPS-0.670
REV370.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

BioAtla Questions & Answers

Q
How do I buy BioAtla (BCAB) stock?
A

You can purchase shares of BioAtla (NASDAQ: BCAB) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are BioAtla's (BCAB) competitors?
A

There are no as such competitors for BioAtla.

Q
What is the target price for BioAtla (BCAB) stock?
A

The latest price target for BioAtla (NASDAQ: BCAB) was reported by Credit Suisse on Thursday, May 5, 2022. The analyst firm set a price target for 5.00 expecting BCAB to rise to within 12 months (a possible 116.45% upside). 3 analyst firms have reported ratings in the last year.

Q
Current Stock Price for BioAtla (BCAB)?
A

The stock price for BioAtla (NASDAQ: BCAB) is $2.31 last updated May 20, 2022, 8:00 PM UTC.

Q
Does BioAtla (BCAB) pay a dividend?
A

There are no upcoming dividends for BioAtla.

Q
When is BioAtla (NASDAQ:BCAB) reporting earnings?
A

BioAtla’s Q2 earnings are confirmed for Friday, August 12, 2022.

Q
Is BioAtla (BCAB) going to split?
A

There is no upcoming split for BioAtla.

Q
What sector and industry does BioAtla (BCAB) operate in?
A

BioAtla is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.